Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting
May 13 2020 - 5:00PM
Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company
leveraging its proprietary DNAbilize™ liposomal delivery and
antisense technology to develop a portfolio of targeted nucleic
acid cancer drugs, today announced an upcoming virtual poster
presentation at the 2020 American Society of Clinical Oncology
(ASCO) Annual Meeting, taking place from May 29-31, 2020.
Dr. Maro Ohanian, Department of Leukemia,
University of Texas M.D. Anderson Cancer Center, will discuss the
Phase 2 study design of BP1001 (liposomal Grb2 antisense), the
Company’s lead drug candidate, in combination with decitabine as a
potential treatment for patients diagnosed with acute myeloid
leukemia or high-risk myelodysplastic syndrome.
Details for the virtual poster presentation are as follows:
Date: Friday, May 29, 2020Presentation
Time: 8:00 am Eastern TimeSession:
Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and
AllotransplantAbstract:
TPS7561Poster: 334Title: A phase
II study of BP1001 (liposomal Grb2 antisense oligonucleotide) in
patients with hematologic malignancies
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing
DNAbilize®, a novel technology that has yielded a pipeline of RNAi
nanoparticle drugs that can be administered with a simple
intravenous transfusion. Bio-Path’s lead product candidate,
prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2
study for the treatment of blood cancers and has filed an IND for a
Phase 1 clinical trial for solid tumors. The Company’s second
pipeline candidate is BP1002, which targets the Bcl-2 protein and
is planned to be evaluated for the treatment of lymphoma and
chronic lymphocytic leukemia. In addition, an IND application for
BP1003, a novel liposome-incorporated STAT3 antisense
oligodeoxynucleotide developed by Bio-Path as a specific inhibitor
of STAT3, is expected to be filed in 2020.
For more information, please visit the Company's
website athttp://www.biopathholdings.com.
Contact Information:
Investors
Will O’ConnorStern Investor Relations,
Inc.212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path
Holdings, Inc. 832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Apr 2024 to May 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From May 2023 to May 2024